Journal
CARDIOVASCULAR DRUGS AND THERAPY
Volume 34, Issue 1, Pages 123-131Publisher
SPRINGER
DOI: 10.1007/s10557-020-06946-6
Keywords
Myocardial infarction; DAMPs; Innate immunity; DNA; Pyroptosis
Funding
- British Heart Foundation [PG/19/51/34493, PG/18/44/33790, PG/16/85/324710]
- BHF Clinical Research Training Fellowship [FS/18/80/33937]
- Biomedical Research Council [BRC429/CV/SG/101320]
Ask authors/readers for more resources
Despite an increase in the rates of survival in patients suffering myocardial infarction, as yet there is no therapy specifically targeting ischaemia and reperfusion injury of the myocardium. With a greater understanding of immune activation during infarction, more potential treatment targets are now being identified. The innate immune system is believed to play an important role in the myocardium after ischaemia-driven cardiomyocyte death. The release of intracellular contents including DNA into the extracellular space during necrosis and cell rupture is now believed to create a pro-inflammatory milieu which propagates the inflammatory process. DNA and DNA fragments have been shown to activate the innate immune system by acting as Danger-Associated Molecular Patterns (DAMPs), which act as ligands on toll-like receptors (TLRs). Stimulation of TLRs, in turn, can activate intracellular cell death pathways such as pyroptosis. Here, we review the role of DNA fragments during ischaemia and reperfusion, and assess their potential as a target in the quest to preserve cardiomyocyte viability following myocardial infarction.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available